Mutations in the splicing factor SF3B1 are linked to frequent emergence of HLA-DRlow/neg monocytes in lower-risk myelodysplastic neoplasms

Susann Winter; Marie Schneider; Uta Oelschlaegel; Giulia Maggioni; Elena Riva; Marco Gabriele Raddi; Sara Bencini; Benedetta Peruzzi; Desmond Choy; Rita Antunes Dos Reis; Esther Güse; Christopher Lischer; Julio Vera; Jessica A Timms; Nicolas Sompairac; Katja Sockel; Antonella Poloni; Antje Tunger; Matteo Giovanni Della Porta; Valeria Santini; Marc Schmitz; Uwe Platzbecker; Shahram Kordasti

doi:10.1038/s41375-024-02249-z

Mutations in the splicing factor SF3B1 are linked to frequent emergence of HLA-DR^low/neg monocytes in lower-risk myelodysplastic neoplasms

Leukemia. 2024 Apr 17. doi: 10.1038/s41375-024-02249-z. Online ahead of print.

Authors

Susann Winter^#¹, Marie Schneider^#², Uta Oelschlaegel¹, Giulia Maggioni^{3

4}, Elena Riva^{3

4}, Marco Gabriele Raddi⁵, Sara Bencini⁶, Benedetta Peruzzi⁶, Desmond Choy³, Rita Antunes Dos Reis³, Esther Güse^{7

8}, Christopher Lischer^{7

8}, Julio Vera^{7

8}, Jessica A Timms³, Nicolas Sompairac³, Katja Sockel¹, Antonella Poloni⁹, Antje Tunger^{10

11}, Matteo Giovanni Della Porta^{4

12}, Valeria Santini⁵, Marc Schmitz^{10

11

13}, Uwe Platzbecker^#^{2

13

14}, Shahram Kordasti^#^{15

16

17}

Affiliations

¹ Department of Internal Medicine I, University Hospital Carl Gustav Carus, Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany.
² Department of Hematology, Cellular Therapy, Hemostaseology and Infectious Disease, University of Leipzig Medical Center, Leipzig, Germany.
³ Comprehensive Cancer Centre, School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.
⁴ IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
⁵ MDS Unit, Hematology, AOU Careggi - Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
⁶ Flow Cytometry Diagnostic Center and Immunotherapy (CDCI), AOU Careggi, Florence, Italy.
⁷ Laboratory of Systems Tumor Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg, and Universitätsklinikum Erlangen, Erlangen, Germany.
⁸ Deutsches Zentrum Immuntherapie and Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
⁹ Department of Clinical and Molecular Sciences, Università Politecnica delle Marche, Ancona, Italy.
¹⁰ Institute of Immunology, Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany.
¹¹ National Center for Tumor Diseases (NCT); German Cancer Research Center (DKFZ); Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden; Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.
¹² Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
¹³ German Cancer Consortium (DKTK), Partner Site Dresden, and German Cancer Research Center (DKFZ), Heidelberg, Germany.
¹⁴ German MDS Study Group (D-MDS), Leipzig, Germany.
¹⁵ Comprehensive Cancer Centre, School of Cancer and Pharmaceutical Sciences, King's College London, London, UK. shahram.kordasti@kcl.ac.uk.
¹⁶ Department of Clinical and Molecular Sciences, Università Politecnica delle Marche, Ancona, Italy. shahram.kordasti@kcl.ac.uk.
¹⁷ Haematology Department, Guy's Hospital, London, UK. shahram.kordasti@kcl.ac.uk.

^# Contributed equally.

PMID: 38632316
DOI: 10.1038/s41375-024-02249-z

No abstract available

Grants and funding